A5073525092- Tuberculosis Research and Epidemiology
- Pharmacovigilance and Adverse Drug Reactions
- Pneumocystis jirovecii pneumonia detection and treatment
- Biosimilars and Bioanalytical Methods
- HIV/AIDS drug development and treatment
- Antibiotic Use and Resistance
- COVID-19 Clinical Research Studies
- Infectious Diseases and Tuberculosis
- Vaccine Coverage and Hesitancy
- Computational Drug Discovery Methods
- Pneumonia and Respiratory Infections
- Global Maternal and Child Health
- Diverse Scientific Research Studies
- HIV Research and Treatment
Makerere University
2022-2025
Infectious Diseases Institute
2022-2025
<ns3:p>Introduction Antimicrobial resistance is a global health threat and people living with HIV are at an increased risk. Inappropriate antibiotic use one of the major driving factors for antimicrobial resistance, lot irrational happens in outpatient clinics. This may be worse resource-limited settings which face challenges diagnosis have drug shortages. There limited information about appropriateness prescriptions their safety especially out-patient settings. Our study aims to assess...
Background The COVID-19 pandemic challenged healthcare systems, particularly in settings with high infectious disease burden. We examined the postpandemic long-term impacts of on tuberculosis (TB) services at anti-retroviral therapy (ART) clinics lower-income countries. Methods Using standardised online questionnaires, we conducted a cross-sectional site survey among ART providing TB Africa and Asia from July to September 2023 (site-level information number diagnoses tests). Results Of 45...
Abstract Background Higher doses of rifampicin may improve treatment outcomes and reduce the duration tuberculosis (TB) therapy. However, drug–drug interactions with antiretroviral therapy (ART) safety in people human immunodeficiency virus (HIV) have not been evaluated. Methods This was a randomized, open-label trial where newly diagnosed TB patients were randomized to higher (35 mg/kg) or standard (10 daily-dose rifampicin. ART treatment–naive dolutegravir- efavirenz-based ART. At week 6,...
Completion of tuberculosis (TB) treatment presents several challenges to patients, including long duration, medication adverse-effects and heavy pill burden. WHO emphasize the need for patient-centered TB care, but such approaches require understanding patient experiences perceptions.In 2020, we nested a qualitative study within clinical trial that recruited 128 HIV-TB co-infected adults in Kampala receiving rifampicin-based treatment, alongside anti-retroviral therapy. A purposively...
Tuberculosis (TB) is the leading infectious cause of death globally. Despite WHO recommendations for TB preventive therapy (TPT), challenges persist, including incompletion treatment and adverse drug reactions (ADRs). There limited data on 3-month isoniazid rifapentine (3HP) pharmacokinetics, pharmacogenomics their relation with ADRs. Our study aims to describe pharmacokinetic 3HP used TPT, ADRs association completion rates, TPT outcomes, providing vital insights control strategies in...